scholarly journals Potassium supplementation and heart rate: A meta-analysis of randomized controlled trials

2016 ◽  
Vol 26 (8) ◽  
pp. 674-682 ◽  
Author(s):  
L. Gijsbers ◽  
F.J.M. Mölenberg ◽  
S.J.L. Bakker ◽  
J.M. Geleijnse
Keyword(s):  
Heart Rate ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Potassium Supplementation

scholarly journals Oral potassium supplementation for management of essential hypertension: A meta-analysis of randomized controlled trials

PLoS ONE ◽  
2017 ◽  
Vol 12 (4) ◽  
pp. e0174967 ◽  
Author(s):  
Jalal Poorolajal ◽  
Fatemeh Zeraati ◽  
Ali Reza Soltanian ◽  
Vida Sheikh ◽  
Elham Hooshmand ◽  
...  
Keyword(s):  
Essential Hypertension ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Potassium Supplementation

The Effects of Statins on Physical Activity or Physical Fitness Among Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 27 (5) ◽  
pp. 762-774
Author(s):  
Adelle Gadowski ◽  
Alice J. Owen ◽  
Andrea Curtis ◽  
Natalie Nanayakkara ◽  
Stephane Heritier ◽  
...  
Keyword(s):  
Physical Activity ◽  
Heart Rate ◽  
Confidence Interval ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Maximal Heart Rate ◽  
Exercise Time ◽  
Randomized Controlled ◽  
And Control

This review examines the effects of statins on physical activity and/or fitness, as statins can have adverse muscle effects. A search was done of MEDLINE, Embase, and EBMR databases up to July 2018 for randomized controlled trials comparing statin with placebo or control, measuring physical activity and/or fitness in adults. Sixteen randomized controlled trials (total participants [N] = 2,944) were included, 6 randomized controlled trials contributed data for meta-analysis. Random effects meta-analysis examined differences in physical fitness, maximal exercise time (in seconds) in exercise testing, and maximal heart rate (in beats per minute) between statins and control. No significant difference between statin and control for maximal heart rate (mean difference = 2.8 beats per minute, 95% confidence interval [−7.4, 13.0]; p = .59) nor exercise time (mean difference = 82.8 s, 95% confidence interval [−31.9, 197.4]; p = .516) were seen. There were insufficient studies reporting habitual physical activity to perform a meta-analysis. This review found no evidence for an effect of statins on physical activity or fitness, but data availability is limited.

scholarly journals Benefits of esmolol in sepsis and septic shock in adults: a meta-analysis of randomized controlled trials

2021 ◽  
Author(s):  
Chun Chen ◽  
Jing Zhang ◽  
Zemei Zhou
Keyword(s):  
Heart Rate ◽  
Septic Shock ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Volume Index ◽  
Current Evidence ◽  
Controlled Trials ◽  
Central Venous ◽  
Randomized Controlled ◽  
Sepsis And Septic Shock

Abstract Background Sepsis affects millions of people each year, and brings substantial health and economic burden to the global. Esmolol may have the potential in the treatment of sepsis and septic shock in adults. However, current evidence remains controversial. Methods We systematically searched PubMed, EMBASE and the Cochrane Central Register of Controlled Trials from their inception to September 19, 2020 for randomized controlled trials (RCTs) evaluating the efficacy of esmolol in sepsis and septic shock in adults. A random-effects meta-analysis was performed to combine effect estimates. Two investigators independently screened articles, extracted data, and assessed the quality of included studies. Results Seven RCTs were included with a total of 463 patients with sepsis and/or septic shock. Overall, compared with standard treatment, esmolol significantly decreased 28-day mortality (risk ratio [RR] 0.68, 95% confidence interval [CI] 0.52 to 0.88), and heart rate (standardized mean difference [SMD] -1.83, 95% CI -2.95 to -0.70) and troponin I (TnI) level (SMD − 0.59, 95% CI -1.02 to -0.16) at 24 hours after treatment; no significant effect was found on the length of intensive care unit stay, mean arterial pressure, central venous pressure, central venous oxygen saturation, Stroke Volume Index, tumor necrosis factor-a, interleukin 6, White Blood Cells and PO2/FiO2. Conclusions Esmolol treatment may be safe and effective in decreasing 28-day mortality, controlling heart rate, and preventing myocardial damage, but no evidence of effect on lung injury in sepsis and septic shock after fluid resuscitation early. There were no significant adverse effects on tissue perfusion and oxygen utilization.

scholarly journals Insights into the association of potassium intake with blood pressure: results of a dose-response meta-analysis of randomized controlled trials

2020 ◽  
Vol 79 (OCE2) ◽  
Author(s):  
Tommaso Filippini ◽  
Duarte Torres ◽  
Carla Lopes ◽  
Catarina Carvalho ◽  
Pedro Moreira ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Randomized Controlled Trials ◽  
Dose Response ◽  
Meta Analysis ◽  
Experimental Studies ◽  
Controlled Trials ◽  
Moderate Increase ◽  
Potassium Intake ◽  
Randomized Controlled ◽  
Potassium Supplementation

AbstractIntroduction:Observational studies provide evidence for an association between potassium intake and BP levels. However, uncertainties still exist about the size and the shape of this relation. Conversely, experimental studies have not been used to estimate dose-response curves, since standard methods can only be applied in trials including at least three exposure groups.Materials and Methods:We carried out a systematic review of the evidence concerning the effect of potassium supplementation on blood pressure in epidemiologic experimental studies. Following a PubMed search up to June 20, 2019, we included randomized controlled trials (RCTs) encompassing potassium supplementation as the only intervention for at least four weeks. We used a restricted cubic spline model and the ‘one-stage’ approach to perform a dose-response meta-analysis, a newly-developed statistical procedure which allows inclusion of studies with as few as two categories of exposure (Stat Methods Med Res. 2019;28:1579–1596). Finally, we repeated the analyses stratifying for hypertensive status and use of anti-hypertensive medication.Results:Overall, we included 33 studies carried out in adult population, with potassium supplementation ranging from 30 to 140 mmol/day. RCTs’ duration ranged from 4 up to 26 weeks. Most of the studies have a cross-over design (N = 24), include hypertensive individuals (N = 27) and subjects not under anti-hypertensive medication (N = 27). Overall, an increase of 40, 80 and 120 mmol/day of potassium resulted in reductions of SBP by -5.64 (95% CI - 8.78, -2.50), -4.62 (-6.41, -2.84) and -2.54 mmHg (95% CI -5.14, + 0.06), respectively. Higher potassium intakes also resulted in reduced DBP levels by -3.57 (95% CI -5.55, -1.59), -3.07 (95% CI -5.07, -1.08), and -1.92 mmHg (95% CI -5.65, 1.81). The effect of increasing potassium intake on BP was larger among hypertensives than normotensives, and among pharmacologically untreated hypertensives compared to their treated counterparts. Subgroup analyses according to study design (parallel vs. crossover) yielded similar results.Discussion:With the application of advanced dose-response modeling on RCT results, we found a U-shaped relation between potassium intake and blood pressure. A low to moderate increase in potassium intake resulted in a progressive reduction in blood pressure, which was reversed at higher levels of potassium supplementation. The effect was stronger among untreated hypertensives.Supported by grant GP-EFSA-AFSCO-2017-01 GA09 of the European Food Safety Authority - EFSA. The text reflects only the authors' view; and EFSA is not responsible for any use that may be made of the information it contains.

Sign in / Sign up

Export Citation Format

Share Document